Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares the effectiveness of 3 different oral moisturizers; 17% watery solution of glycerol, OGT oral spray, Aequasyal, and a newly developed Product, Salient.
Background:
A majority of patients in palliative care have problems with dry mouth caused by medication or as a direct result of the mortal condition. Dry mouth will cause a variety of problems that commonly affect the disease negatively and contribute to reduced quality of life in the patient's last stage of life. A Cochrane review from 2011 concludes that "there are several moisturising agents available, but no strong evidence that any topical therapy is effective for relieving the symptom of dry mouth." It also concludes that "Oxygenated glycerol triester (OGT) oral spray is more effective than an aqueous electrolyte spray."1
Objectives:
To compare the effectiveness of 3 different oral moisturisers, ; 17 % watery solution of glycerol, OGT oral spray, Aequasyal® and a newly developed product, Salient®.
Methods/design:
30 patients will be recruited from a Norwegian palliative care unit. Eligibility criteria for participants are:
Patients treated with radiotherapy in head and neck region, are excluded from this trial.
The different moisturizers will be compared in a double blind, cross-over design. All patients will be randomized to all three treatments in the cross-over trial, with a minimum of 24 hours wash-out period between the treatments. Patient responses will be collected at baseline, immediately after exposure and after 2 hours. Medical history and medication will be recorded. Primary outcome variables are the subjective feeling of xerostomia, pain/discomfort and speech disturbance.
Ethical considerations:
An application for approval of this study will be sent to the Regional Ethical Committee (REC). There are no known side effects of the agents or methods that will be applied.
Discussion:
To the investigators knowledge, the proposed randomized controlled trial of the effect of three different oral moisturizers will be the first study of this kind to be performed in patients in palliative institutionalized ward. There are no known adverse effects of the products used in this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Glycerol 17 % | Active Comparator | Oral moisturizer |
|
| Aequasyal (OGT) | Active Comparator | Oral moisturizer |
|
| Salient (new product) | Active Comparator | Oral moisturizer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Glycerol 17% | Device | Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Subjective xerostomia | Measured on a 5-point Likert-scale: Subjective feeling of dry mouth:
| 3 days |
| Measure | Description | Time Frame |
|---|---|---|
| Pain/discomfort | Measured on a 5-point Likert-scale: Subjective feeling pain/discomfort:
| 3 days |
| Speech |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients treated with radiotherapy in head and neck region.
-
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Siri F. Kvalheim, DDS | Contact | 0047 55586488 | Siri.Kvalheim@uib.no | |
| Stein-Atle Lie, PhD | Contact | 0047 55586477 | Stein.Lie@uib.no |
| Name | Affiliation | Role |
|---|---|---|
| Gunhild V Strand, DDS, PhD | University of Bergen, Norway | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Bergen | Recruiting | Bergen | Hordaland | 5099 | Norway |
Anonymous data will be available by request after publication of effect article.
Data will be available after publication of article.
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014987 | Xerostomia |
| ID | Term |
|---|---|
| D012466 | Salivary Gland Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
The different moisturizers will be compared in a double blind, cross-over design. Patient responses will be collected at baseline, immediately after exposure and after 2 hours.
Not provided
Not provided
A Block randomisation is made by a person, other than the one who applies the product. Neither the patient nor the person who records the product or the person who registers data knows which product is used for the intervention. The product is not labeled with name
| Aequasyal (OGT) | Device | Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist. |
|
| Salient (new product) | Device | Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist. |
|
Measured on a 5-point Likert-scale:
Xerostomia regarding impact on ability to speak:
| 3 days |
| Diurnal variation | Measured on a 5-point Likert-scale: At what times are xerostomia most pronounced:
| 3 days |
| Situational dry mouth | Measured on a 3-point Likert-scale:
| 3 days |